Dongwha Pharm.Co.,Ltd (KRX:000020)
South Korea · Delayed Price · Currency is KRW 6,250.00
-10.00 (-0.16%)
At close: Nov 5, 2025
Dongwha Pharm.Co.,Ltd Revenue
Dongwha Pharm.Co.,Ltd had revenue of 125.02B KRW in the quarter ending June 30, 2025, with 8.56% growth. This brings the company's revenue in the last twelve months to 481.53B, up 18.68% year-over-year. In the year 2024, Dongwha Pharm.Co.,Ltd had annual revenue of 464.87B with 28.74% growth.
Revenue (ttm)
481.53B
Revenue Growth
+18.68%
P/S Ratio
0.36
Revenue / Employee
582.96M
Employees
812
Market Cap
173.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 464.87B | 103.77B | 28.74% |
| Dec 31, 2023 | 361.11B | 20.68B | 6.08% |
| Dec 31, 2022 | 340.43B | 47.41B | 16.18% |
| Dec 31, 2021 | 293.02B | 20.94B | 7.70% |
| Dec 31, 2020 | 272.08B | -35.07B | -11.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |